Transition From Intravenous to Subcutaneous Treprostinil in a Pediatric Patient With Pulmonary Hypertension

Pulmonary hypertension (PH) causes significant morbidity and mortality in children, and, while the treatment strategies for PH in adults are well studied and developed, few data exist for pediatric patients. In adult patients, successful transitions from intravenous (IV) epoprostenol to subcutaneous (SC) treprostinil are reported, but this information is limited for pediatric patients. Furthermore, while there are reports of SC to IV treprostinil in adults, there are no reports of the transition from IV to SC treprostinil. This case report recounts a successful transition from IV treprostinil to SC treprostinil in a pediatric patient with WHO Class 3, PH, secondary to interstitial lung disease.